Bramson's Sherborne takes Electra stake to almost 25%

Alice Rigby
clock

Edward Bramson's Sherborne Investors has further upped its interest in Electra Private Equity as it plans its next move following an unsuccessful attempt to take control of the trust last year.

His company, Sherborne Investors, increased its stake from 22.1% in December to 23.4% on Friday, according to a stock exchange filing released today. Following hot on the heels of earlier stakebuilding moves last month, Sherborne's position is fast approaching 25%, a stake analysts at Numis suggested the Electra board would “find it increasingly hard to ignore”. Bramson (pictured) has been gradually increasing his stake in Electra Private Equity over the last year and has been actively campaigning to take control of the trust during that period. In July, Electra’s chairman and b...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Specialist

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
European private equity yet to spend €270bn worth of capital

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Early-stage biopharma: An opportunity for strategic investment

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read
Trustpilot